CD38 inhibition to modulate NAD metabolism
PrimaryNapa Therapeutics' mechanistic theory is that small-molecule inhibition of CD38, an NAD-metabolism-linked target, can intervene in a fundamental aging process and thereby affect age-related disease biology. The company is described as developing small molecules against a novel aging-related target based on Eric Verdin lab research in NAD metabolism; patent records identify Napa/Buck compounds as heteroaryl amide inhibitors of CD38. Testable predictions are that Napa's compounds should inhibit CD38 pharmacologically, produce measurable changes in NAD-metabolism biomarkers, and improve disease-relevant phenotypes in preclinical models. The provided project record notes therapeutic effects of a newly developed CD38 inhibitor in a collagen-induced arthritis mouse model, supporting this as a disease-modifying NAD-metabolism program rather than merely a discovery platform claim.
Popperian evaluation
The premise is credible: CD38 is tied to NAD metabolism, and the theory makes a direct pharmacology claim rather than a vague aging claim. The weak point is breadth. Moving NAD biomarkers through CD38 inhibition is plausible; treating a fundamental aging process across age-related disease biology is a larger claim than the evidence here can carry.
Supporting evidence: Small-molecule inhibition of CD38 is proposed as a way to modulate NAD metabolism in aging biology.; Patent records identify Napa/Buck compounds as heteroaryl amide inhibitors of CD38.; The program is described as based on Eric Verdin lab research in NAD metabolism.
Counter evidence: The provided evidence does not show human biomarker data.; The arthritis mouse result supports disease biology, but it does not prove that CD38 inhibition changes aging itself.
The theory explains one reported observation reasonably well: a CD38 inhibitor produced therapeutic effects in a collagen-induced arthritis mouse model. But the causal chain is still thin. The result could fit CD38-linked NAD biology, immune modulation, or off-target pharmacology. Without biomarker movement and target-engagement controls, the explanation is plausible rather than dominant.
Supporting evidence: A newly developed small-molecule CD38 inhibitor exerted therapeutic effects in a collagen-induced arthritis mouse model.; The stated theory predicts disease-relevant phenotypic improvement after CD38 inhibition.
Counter evidence: The evidence record itself flags the assumption that therapeutic effects are mediated through CD38 inhibition and NAD-metabolism changes rather than unrelated off-target activity.; The collagen-induced arthritis model tests inflammatory disease biology, not broad organismal aging.
This is the strongest Popperian feature. The theory can fail in several clean ways: the compounds might not inhibit CD38, NAD-metabolism biomarkers might not move, or disease phenotypes might not improve despite target engagement. Better still, the off-target question can be tested with selectivity panels, rescue experiments, CD38 genetic controls, and dose-response links between inhibition, biomarkers, and phenotype.
Supporting evidence: The theory predicts that Napa's compounds should pharmacologically inhibit CD38.; The theory predicts measurable changes in NAD-metabolism biomarkers.; The theory predicts improved disease-relevant phenotypes in preclinical models.
Counter evidence: The provided record does not specify quantitative thresholds for CD38 inhibition, NAD biomarker change, or phenotype improvement.; A single positive mouse-model observation does not define what result would make the broader aging claim fail.
Reasoning tree
Public endorsements
The public record ties Alex Zhavoronkov to Napa as a founder through Insilico Medicine, and the Napa launch materials state that the company was created to develop drugs against age related disease from Buck Institute research. That is a public endorsement of the program direction. The evidence here does not show Zhavoronkov personally discussing CD38 by name, so the endorsement is stronger on the company thesis than on the exact target-level wording.
Evidence publication IDs: 795b5eb8-6de7-493f-8352-85385b050a3c, 999ad3b6-6c47-440c-947a-782616ae7f23
There is no direct public statement from David Gill in the provided evidence about Napa Therapeutics, CD38 inhibition, or NAD-metabolism mechanisms. The only record is a generic Juvenescence resource page and does not attribute any view on this theory to him.
The provided evidence ties Declan Doogan to Juvenescence and to broader longevity discussions, but it does not show him publicly discussing Napa Therapeutics, CD38 inhibition, or NAD-metabolism-based aging biology. On this record, he stays silent on the specific theory.
No provided quote or publication shows Eileen Jennings-Brown discussing Napa Therapeutics, CD38 inhibition, NAD metabolism, or the underlying aging mechanism. The evidence places her in technology leadership at Juvenescence and on an AI-in-biotech panel, but that is not a public statement on this theory.
Verdin is publicly tied to the theory through the CD38 inhibitor patent record: EP4225310A4 lists him as an inventor on 'heteroaryl amide inhibitors of CD38' and names Napa Therapeutics and the Buck Institute as applicants/assignees. That is stronger than a generic mention. The provided quotes discuss aging broadly, not this mechanism.